Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. blms 4 tb

BLMs 4 TB SIGNED

Beta-lactams for Tuberculosis Treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BLMs 4 TB project word cloud

Explore the words cloud of the BLMs 4 TB project. It provides you a very rough idea of what is the project "BLMs 4 TB" about.

time    worldwide    relapse    cephalosporins    undergo    50    last    track    blms    strains    prevent    carbapenems    takes    resistant    life    cephems    dosage    lactams    combo    anti    meropenem    specificities    mdr    urgently    oacute    never    iia    regarded    treatments    clinical    drug    killing    poor    unclear    extensively    microscopy    subset    prospects    agents    tuberculosis    pd    questions    pharmacodynamics    led    trial    quality    head    arose    infectious    family    treatment    pharmacokinetic    proteomic    infections    beta    optimal    barros    pk    market    beneficiary    pursued    administration    record    transcriptomic    renewed    hope    dr    dim    frequency    blm    discontinued    glaxosmithkline    adherence    tb    longer    safest    treat    xdr    bacterial    positive    linked    gsk    resistance    unpleasant    severe    patients    techniques    antibiotics    therapies    24    generation    disease    lapse    outcomes    carbapenem    validated    point    outcome    virtually    garc    therapy    inform    modeling    molecular    shorten    infected    trials    microbiology    report    ram    deadly    decades    months    iacute    data    leads    first    mathematical    ineffective    answer   

Project "BLMs 4 TB" data sheet

The following table provides information about the project.

Coordinator		 FUNDACION AGENCIA ARAGONESA PARA LA INVESTIGACION Y EL DESARROLLO 

Organization address
address: PASEO MARIA AGUSTIN 36 EDIFICIO PIGNATELLI PTA 30 PL 2
city: ZARAGOZA
postcode: 50004
website: www.araid.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Total cost 170˙121 €
 EC max contribution 170˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION AGENCIA ARAGONESA PARA LA INVESTIGACION Y EL DESARROLLO ES (ZARAGOZA) coordinator 170˙121.00

Map

 Project objective

Tuberculosis (TB) is the most deadly infectious disease worldwide. TB therapy takes 6 months with unpleasant side effects that leads to poor adherence and the development of drug resistance. Patients infected with multi (MDR) or extensively (XDR) drug resistant strains must undergo longer treatments (up to 24 months) associated with even severe side effects and only 30-50% positive treatment outcomes. New treatments are urgently needed.

Beta-lactams (BLMs) are the safest antibiotics in the market with a long track record of clinical use to treat bacterial infections. They were, however, traditionally regarded as ineffective for TB therapy to the point that research was virtually discontinued for the last three decades. A renewed interest recently arose after a report of Phase IIa clinical trial validated the potential of meropenem (a carbapenem). This study was led by Dr. Barros, Head TB unit GlaxoSmithKline (GSK) (the beneficiary of this proposal). In addition, Dr. Ramón-García (the applicant) just identified first-generation cephalosporins (cephems), a subset of the BLM family never pursued for TB therapy, as potential anti-TB agents. Promoting BLM development is the best immediate hope for TB patients that currently have very dim life prospects.

Carbapenems and cephems have different anti-bacterial killing properties, pharmacokinetic (PK) and pharmacodynamics (PD) parameters. These specificities affect therapy design for an optimal clinical outcome. Although promising, it is still unclear how BLMs should be included in new combo therapies (i.e. dosage, duration and frequency of administration) to shorten the duration of TB therapy, prevent relapse and treat M(X)DR-TB.

To answer these questions, I will use time-lapse microscopy linked to mathematical PK/PD modeling, transcriptomic and proteomic studies and clinical microbiology techniques to provide high quality molecular and PK/PD pre-clinical data to inform the design of future BLM TB clinical trials.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BLMS 4 TB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BLMS 4 TB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NSTree (2020)

Understanding substrate delivery for cell wall biosynthesis in plants

Read More  

CREDit (2020)

Chronological REference Datasets and Sites (CREDit) towards improved accuracy and precision in luminescence-based chronologies

Read More  

RipGEESE (2020)

Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved

Read More